Search
Search
About
Log in
Join
Experiences with
Castration
Posts
Communities
1,138 public posts
Filter results
11-Ketotestosterone [11KT] (& 11-Ketodihydrotestosterone [11KDHT])
From a 2020 U.S. study [3]: "In CRPC patients, administration of {Abi & medical
castration
} lowered all four 11-oxygenated androgens to below the lower limits of quantitation ..." *** ... but 11KT remains of interest to those whose only AR-axis targeted therapy is
castration
.
From a 2020 U.S. study [3]: "In CRPC patients, administration of {Abi & medical
castration
} lowered all four 11-oxygenated androgens to below the lower limits of quantitation ..." *** ... but 11KT remains of interest to those whose only AR-axis targeted therapy is
castration
.
pjoshea13
in
Advanced Prostate Cancer
3 years ago
Considering orchiectomy?
I’m considering an orchiectomy instead of continuing expensive medical
castration
treatments. Any advice/experiences with one vs the other? I’m 71 and Gleason 7/8.
I’m considering an orchiectomy instead of continuing expensive medical
castration
treatments. Any advice/experiences with one vs the other? I’m 71 and Gleason 7/8.
Woodman33
in
Advanced Prostate Cancer
3 years ago
Update on lutetium treatment at Hopkins
177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic,
Castration
Resistant Prostate Cancer I have received all three treatments as of May 20. They were six weeks apart. My initial PSA was 90.
177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic,
Castration
Resistant Prostate Cancer I have received all three treatments as of May 20. They were six weeks apart. My initial PSA was 90.
wpopomaronis
in
Advanced Prostate Cancer
3 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Off label use of Mekinist (Trametinib)
MEK-ERK signaling is a therapeutic target in metastatic
resistant prostate cancer Prostate cancer and prostatic diseases 22(4), 531-538, 2019 "ERK1 is the immediate downstream target of MEK1/2, which is druggable with trametinib, an approved therapeutic for melanoma."
MEK-ERK signaling is a therapeutic target in metastatic
resistant prostate cancer Prostate cancer and prostatic diseases 22(4), 531-538, 2019 "ERK1 is the immediate downstream target of MEK1/2, which is druggable with trametinib, an approved therapeutic for melanoma."
Graham49
in
Advanced Prostate Cancer
3 years ago
Dr Oliver Sartor of Tulane Univ. on Cabazitaxel for later stage Castration Resistant mPCa (CRmPCa). Vs Docetaxel and Zytiga.
https://www.targetedonc.com/view/cabazitaxel-advances-later-line-treatment-in-metastatic-crpc-setting
https://www.targetedonc.com/view/cabazitaxel-advances-later-line-treatment-in-metastatic-crpc-setting
Spyder54
in
Advanced Prostate Cancer
3 years ago
What genetics tests are need to done
Anybody can tell me what are all genetic tests which can helpful for different medicine like I already have done MSI, BRCA1,BRCA2 if any other tests can give more info or open doors to other treatment right now
castration
resistant Gleason 4+4 8 abiraterone plus have made steroid switch so dexamethesone
Anybody can tell me what are all genetic tests which can helpful for different medicine like I already have done MSI, BRCA1,BRCA2 if any other tests can give more info or open doors to other treatment right now
castration
resistant Gleason 4+4 8 abiraterone plus have made steroid switch so dexamethesone
Nirman
in
Advanced Prostate Cancer
3 years ago
New Tool Could Help Predict Outcomes with 177Lu-PSMA in Metastatic Castration-Resistant Prostate Cancer
https://www.onclive.com/view/new-tool-could-help-predict-outcomes-with-177lu-psma-in-metastatic-
castration
-resistant-prostate-cancer
https://www.onclive.com/view/new-tool-could-help-predict-outcomes-with-177lu-psma-in-metastatic-
castration
-resistant-prostate-cancer
RMontana
in
Active Surveillance - Prostate Cancer
3 years ago
Ipatasertib+abiraterone effective in men with PTEN-loss
A large Phase 3 trial found that ipatasertib combined with abiraterone significantly increased radiographic progression-free survival by 2 months in men who were previously untreated, metastatic and
castration
-resistant with PTEN loss.
A large Phase 3 trial found that ipatasertib combined with abiraterone significantly increased radiographic progression-free survival by 2 months in men who were previously untreated, metastatic and
castration
-resistant with PTEN loss.
Tall_Allen
in
Advanced Prostate Cancer
3 years ago
BRCA2 mutation and PARP inhibitor in the castration sensitive
However there does not seem to be the volume of evidence as is the case for PARP inhibitors and the studies are on the
castration
resistant only.
However there does not seem to be the volume of evidence as is the case for PARP inhibitors and the studies are on the
castration
resistant only.
Purple-Bike
in
Advanced Prostate Cancer
3 years ago
CD38
The primary objective of this study was to quantify the expression and clinical impact of CD38+ prostate TIICs as tumours progressed from being
castration
sensitive to
castration
resistant, with the long-term goal of repurposing CD38-directed therapies for mCRPC treatment."
The primary objective of this study was to quantify the expression and clinical impact of CD38+ prostate TIICs as tumours progressed from being
castration
sensitive to
castration
resistant, with the long-term goal of repurposing CD38-directed therapies for mCRPC treatment."
pjoshea13
in
Advanced Prostate Cancer
3 years ago
And the superiority of Abiraterone before switching to Enalutamide (vs. the opposite sequence) Revisited.
used for the treatment of metastatic
castration
-resistant prostate cancer.
used for the treatment of metastatic
castration
-resistant prostate cancer.
MateoBeach
in
Advanced Prostate Cancer
3 years ago
Article: A Systematic Review of the Effectiveness and Toxicities of Lutetium-177-labeled PSMA-targeted Radioligand Therapy >>>
June 4, 2021 In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen highlight a systematic review and meta-analysis examining the effectiveness and toxicities of lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic
castration
-resistant prostate
June 4, 2021 In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen highlight a systematic review and meta-analysis examining the effectiveness and toxicities of lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic
castration
-resistant prostate
GregHouston
in
Advanced Prostate Cancer
3 years ago
2020 case report showing promise from using the mTor inhibiting drug Everolimus
Deepak Kilaric aFoundation Medicine, Cambridge, MA, USA; bDepartment of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA; cDepartment of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA Keywords PTEN · Prostate cancer · Everolimus ·
Castration
Deepak Kilaric aFoundation Medicine, Cambridge, MA, USA; bDepartment of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA; cDepartment of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA Keywords PTEN · Prostate cancer · Everolimus ·
Castration
Graham49
in
Advanced Prostate Cancer
3 years ago
Which is better regarding Cognitive and Fatigue Side Effects: Abiratirone + Pred. or Enzalutamide in mCRPC?
) and enzalutamide (ENZ) are commonly prescribed for metastatic
castration
-resistant prostate cancer (mCRPC).
) and enzalutamide (ENZ) are commonly prescribed for metastatic
castration
-resistant prostate cancer (mCRPC).
MateoBeach
in
Advanced Prostate Cancer
3 years ago
Thromboxane A2 [TxA2]
U.S. (2005) [3]: "
reduces platelet thromboxane A2 receptor density and aggregability" "We studied surgically and/or medically castrated men with prostate cancer (group A, n = 8, aged 71 +/- 8 years) and age-matched, uncastrated urology patients (group B, n = 7, aged 67 +/- 9 years).
U.S. (2005) [3]: "
reduces platelet thromboxane A2 receptor density and aggregability" "We studied surgically and/or medically castrated men with prostate cancer (group A, n = 8, aged 71 +/- 8 years) and age-matched, uncastrated urology patients (group B, n = 7, aged 67 +/- 9 years).
pjoshea13
in
Advanced Prostate Cancer
3 years ago
Enzalutamide Resistance & Treatment-Emergent AR Changes
PMID: 33849963 DOI: 10.1158/1078-0432.CCR-20-4616 Abstract Purpose: Enzalutamide is a second-generation androgen receptor (AR) inhibitor which has improved overall survival (OS) in metastatic
castration
resistant prostate cancer (CRPC). However, nearly all patients develop resistance.
PMID: 33849963 DOI: 10.1158/1078-0432.CCR-20-4616 Abstract Purpose: Enzalutamide is a second-generation androgen receptor (AR) inhibitor which has improved overall survival (OS) in metastatic
castration
resistant prostate cancer (CRPC). However, nearly all patients develop resistance.
pjoshea13
in
Advanced Prostate Cancer
3 years ago
BAT - Reversing the effects of ADT in men with metastatic CRPC.
"Bipolar androgen therapy (BAT) is the cyclic administration of high dose testosterone as a novel treatment for metastatic
castration
resistant prostate cancer (mCRPC).
"Bipolar androgen therapy (BAT) is the cyclic administration of high dose testosterone as a novel treatment for metastatic
castration
resistant prostate cancer (mCRPC).
pjoshea13
in
Advanced Prostate Cancer
3 years ago
Advice on dosage for Abiraterone
Oncologist is prescribing Abiraterone as 2nd line treatment now that I am
castration
resistant (mcrpc). Have read various info on taking 1000mg/day vs lower dosage of 250mg/day.
Oncologist is prescribing Abiraterone as 2nd line treatment now that I am
castration
resistant (mcrpc). Have read various info on taking 1000mg/day vs lower dosage of 250mg/day.
Ronnie7C
in
Advanced Prostate Cancer
3 years ago
Anyone have idea about role of modified citrus pectin in advanced metastatic castration resistant prostate cancer?
If anyone have any idea or used it please let me know?
If anyone have any idea or used it please let me know?
Nirman
in
Advanced Prostate Cancer
3 years ago
Circulating Tumor Cells & Inflammation
"The neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and circulating tumor cells (CTCs) have been associated with survival in
castration
-resistant prostate cancer (CRPC). However, no study has examined the prognostic value of NLR and PLR in the context of CTCs."
"The neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and circulating tumor cells (CTCs) have been associated with survival in
castration
-resistant prostate cancer (CRPC). However, no study has examined the prognostic value of NLR and PLR in the context of CTCs."
pjoshea13
in
Advanced Prostate Cancer
3 years ago
1
...
21
22
23
...
57
Next page
10
20
30
40
50
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
1015 results
Fight Prostate Cancer
67 results
Prostate Cancer Network
25 results
View top 10 communities
Sort by
Most Relevant
Newest